Mary Clare Masters1, Jeremiah Perez2, Kunling Wu2, Ronald J Ellis3, Karl Goodkin4, Susan L Koletar5, Adriana Andrade6, Jingyan Yang7, Todd T Brown8, Frank J Palella1, Ned Sacktor8, Katherine Tassiopoulos2, Kristine M Erlandson9. 1. Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 2. Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA. 3. University of California, San Diego, San Diego, California, USA. 4. University of Nebraska Medical Center, Omaha, Omaha, Nebraska, USA. 5. The Ohio State University, Columbus, Ohio, USA. 6. DHHS/NIH/NIAID/DAIDS, Rockville, Maryland, USA. 7. Columbia University, New York, New York, USA. 8. Johns Hopkins University, Baltimore, Maryland, USA. 9. University of Colorado- Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract
BACKGROUND: Neurocognitive impairment (NCI) and frailty are more prevalent among persons with human immunodeficiency virus (HIV, PWH) compared to those without HIV. Frailty and NCI often overlap with one another. Whether frailty precedes declines in neurocognitive function among PWH or vice versa has not been well established. METHODS: AIDS Clinical Trials Group (ACTG) A5322 is an observational cohort study of older PWH. Participants undergo annual assessments for NCI and frailty. ACTG A5322 participants who developed NCI as indexed by tests of impaired executive functioning and processing speed during the first 3 years were compared to persons who maintained normal cognitive function; those who demonstrated resolution of NCI were compared to those who had persistent NCI. Participants were similarly compared by frailty trajectory. We fit multinomial logistic regression models to assess associations between baseline covariates (including NCI) and frailty, and associations between baseline covariates (including frailty) and NCI. RESULTS: In total, 929 participants were included with a median age of 51 years (interquartile range [IQR] 46-56). At study entry, 16% had NCI, and 6% were frail. Over 3 years, 6% of participants developed NCI; 5% developed frailty. NCI was associated with development of frailty (odds ratio [OR] = 2.06; 95% confidence interval [CI] = .94, 4.48; P = .07). Further adjustment for confounding strengthened this association (OR = 2.79; 95% CI = 1.21, 6.43; P = .02). Baseline frailty however was not associated with NCI development. CONCLUSIONS: NCI was associated with increased risk of frailty, but frailty was not associated with development of NCI. These findings suggest that the presence of NCI in PWH should prompt monitoring for the development of frailty and interventions to prevent frailty in this population.
BACKGROUND: Neurocognitive impairment (NCI) and frailty are more prevalent among persons with human immunodeficiency virus (HIV, PWH) compared to those without HIV. Frailty and NCI often overlap with one another. Whether frailty precedes declines in neurocognitive function among PWH or vice versa has not been well established. METHODS: AIDS Clinical Trials Group (ACTG) A5322 is an observational cohort study of older PWH. Participants undergo annual assessments for NCI and frailty. ACTG A5322 participants who developed NCI as indexed by tests of impaired executive functioning and processing speed during the first 3 years were compared to persons who maintained normal cognitive function; those who demonstrated resolution of NCI were compared to those who had persistent NCI. Participants were similarly compared by frailty trajectory. We fit multinomial logistic regression models to assess associations between baseline covariates (including NCI) and frailty, and associations between baseline covariates (including frailty) and NCI. RESULTS: In total, 929 participants were included with a median age of 51 years (interquartile range [IQR] 46-56). At study entry, 16% had NCI, and 6% were frail. Over 3 years, 6% of participants developed NCI; 5% developed frailty. NCI was associated with development of frailty (odds ratio [OR] = 2.06; 95% confidence interval [CI] = .94, 4.48; P = .07). Further adjustment for confounding strengthened this association (OR = 2.79; 95% CI = 1.21, 6.43; P = .02). Baseline frailty however was not associated with NCI development. CONCLUSIONS: NCI was associated with increased risk of frailty, but frailty was not associated with development of NCI. These findings suggest that the presence of NCI in PWH should prompt monitoring for the development of frailty and interventions to prevent frailty in this population.
Authors: Ronald J Ellis; Jayraan Badiee; Florin Vaida; Scott Letendre; Robert K Heaton; David Clifford; Ann C Collier; Benjamin Gelman; Justin McArthur; Susan Morgello; J Allen McCutchan; Igor Grant Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Kristine M Erlandson; Derek K Ng; Lisa P Jacobson; Joseph B Margolick; Adrian S Dobs; Frank J Palella; Jordan E Lake; Hanhvy Bui; Lawrence Kingsley; Todd T Brown Journal: J Infect Dis Date: 2017-01-15 Impact factor: 5.226
Authors: E Kelaiditi; M Cesari; M Canevelli; G Abellan van Kan; P-J Ousset; S Gillette-Guyonnet; P Ritz; F Duveau; M E Soto; V Provencher; F Nourhashemi; A Salvà; P Robert; S Andrieu; Y Rolland; J Touchon; J L Fitten; B Vellas Journal: J Nutr Health Aging Date: 2013-09 Impact factor: 4.075
Authors: Charlotte S Hakkers; Joop E Arends; Guido E van den Berk; Monique H M Ensing; Imke Hooijenga; Matthijs Vink; Martine J E van Zandvoort; Andy I M Hoepelman Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Hal H Atkinson; Caterina Rosano; Eleanor M Simonsick; Jeff D Williamson; Cralen Davis; Walter T Ambrosius; Stephen R Rapp; Matteo Cesari; Anne B Newman; Tamara B Harris; Susan M Rubin; Kristine Yaffe; Suzanne Satterfield; Stephen B Kritchevsky Journal: J Gerontol A Biol Sci Med Sci Date: 2007-08 Impact factor: 6.053
Authors: Laura D Baker; Suzanne M Barsness; Soo Borson; George R Merriam; Seth D Friedman; Suzanne Craft; Michael V Vitiello Journal: Arch Neurol Date: 2012-11
Authors: Sean A P Clouston; Paul Brewster; Diana Kuh; Marcus Richards; Rachel Cooper; Rebecca Hardy; Marcie S Rubin; Scott M Hofer Journal: Epidemiol Rev Date: 2013-01-24 Impact factor: 6.222